EXTH-25. THE CSF PENETRATION OF THE PROCASPASE-ACTIVATING COMPOUND (PAC-1) IN COMBINATION WITH TEMOZOLOMIDE (TMZ) IN A NONHUMAN PRIMATE CSF ACCESS MODEL

BACKGROUND: The synergistic activity of temozolomide (TMZ) administered in combination with procaspase-activating compound (PAC-1) has been reported in pre-clinical mouse models and canine patients, leading to clinical trials in adults with glioblastoma. To optimize pediatric clinical trial design,...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Neuro Oncol
Auteurs principaux: Lester McCully, Cynthia, Shankarappa, Priya, Garcia, Rafael Cruz, Peer, Cody, Zakharov, Alexander, Fischer, James, Lyubimov, Alexander, Hergenrother, Paul, Thomas, Marvin, Figg, William, Warren, Katherine
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2020
Sujets:
Preclinical Experimental Therapeutics
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7651507/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.379
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires